Ono Pharmaceutical (4528) · InitiativeDropped
Building the Orientum Innovation drug discovery network
First written in FY2016. 1 of 3 entries say "Restated". Latest entry: FY2018.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
Open Innovation Through Industry-Government-Academia Collaboration and Early CommercializationA theme 23 companies write about · 0 as a headwind · 23 as a tailwind
0 other companies' latest entry also says "Dropped".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 23 companies compared. The sentences above are computed from all 23.Full recordFilings, disclosures and news, newest first
- FY2018DroppedAnnual reportThe current annual securities report contains no reference to the name “Orientum Innovation”; the initiative is described instead as open innovation and individual drug discovery partnerships.
- FY2017RestatedAnnual report
「To further accelerate this initiative, the company will continue developing in Japan and overseas a new type of industry-academia collaboration network, Orientum Innovation, by providing its highly novel proprietary compounds to multiple universities and research institutions with cutting-edge knowledge and technologies, thereby enabling faster-than-ever exploration of pharmaceutical applications.」
The company has reaffirmed its policy of developing Orientum Innovation in Japan and overseas to accelerate the search for applications for its compounds. - FY2016First statedAnnual report
「The company will continue developing a new type of industry-academia collaboration network, Orientum Innovation, in Japan and overseas.」
The company is presenting a framework under which proprietary compounds are provided to multiple universities and research institutions to accelerate the search for potential pharmaceutical applications.